{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:49:41Z","timestamp":1790790581725,"version":"4.1.0"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To present a rare, to our knowledge previously undescribed, case of successful AFRS management using stapokibart (CM310).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>The laboratory, immunological, symptom scores and imaging datas before and after stapokibart treatment were evaluated to determine the effect of stapokibart on AFRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After four weeks of treatment, the patient showed significant clinical improvement, including a marked reduction in nasal polyp size and the near-complete return of normal olfaction. By week 16, lab tests confirmed a substantial drop in eosinophils and IgE, and a follow-up CT scan showed complete resolution of sinus inflammation. The patient reported high satisfaction due to a major improvement in quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pioneering case demonstrates that stapokibart, a novel anti-IL-4R\u03b1 antibody, is a promising and effective treatment for refractory AFRS, showing a rapid onset of action and sustained control of type 2 inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2025.1746033","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:41:16Z","timestamp":1768372876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful use of stapokibart as a biological therapy for allergic fungal rhinosinusitis: a case report"],"prefix":"10.3389","volume":"6","author":[{"given":"Hua","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province Clinical Research Center for Deafness and Vertigo","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jie","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province Clinical Research Center for Deafness and Vertigo","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province Clinical Research Center for Deafness and Vertigo","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha-Zhou","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province Clinical Research Center for Deafness and Vertigo","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province Clinical Research Center for Deafness and Vertigo","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Qing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province Clinical Research Center for Deafness and Vertigo","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province Clinical Research Center for Deafness and Vertigo","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/alr.23582","article-title":"Allergic fungal rhinosinusitis diagnosis, management, associated conditions, pathophysiology, and future directions: summary of a multidisciplinary workshop","volume":"15","author":"Roland","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4193\/Rhin24.397","article-title":"The evaluation of therapeutic outcomes of biologics in allergic fungal rhinosinusitis: a systematic review and meta-analysis","volume":"63","author":"Aljubran","year":"2025","journal-title":"Rhinology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102076","DOI":"10.1016\/j.eclinm.2023.102076","article-title":"Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"61","author":"Zhang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102467","DOI":"10.1016\/j.eclinm.2024.102467","article-title":"Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial","volume":"69","author":"Zhang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/s41591-025-03651-5","article-title":"Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4193\/Rhin24.573","article-title":"Olfactory outcomes following biological therapy in chronic rhinosinusitis: a systematic review and meta-analysis","volume":"63","author":"Patel","year":"2025","journal-title":"Rhinology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"110721","DOI":"10.1016\/j.isci.2024.110721","article-title":"Stapokibart (CM310) targets IL-4Ralpha for the treatment of type 2 inflammation","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1746033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:54:06Z","timestamp":1771916046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1746033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":10,"alternative-id":["10.3389\/falgy.2025.1746033"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1746033","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1746033"}}